PTC Therapeutics, Inc. today announced positive results fro...

PTC Therapeutics, Inc. today announced positive results from a long-term real-world study of Translarna (Ataluren), a small molecule therapy. Data from 241 patients showed that Translarna delayed bedside mobility by more than 5 years and reduced lung function by an average of 1.8 years in boys with nonsense mutant Duchenne muscular dystrophy compared with standard therapy alone. $PTC Therapeutics(PTCT.US)$